Tempus AI, Inc. reported second-quarter 2026 results with revenue of $382.5M, up 22% from $314.6M a year earlier, and net income of $5.6M versus a net loss of $(42.8)M in Q2 2025.
Financial Highlights
- Revenue: $382.5M for Q2 2026, compared with $314.6M in Q2 2025; YoY change 22%.
- Net income: $5.6M for Q2 2026, versus a net loss of $(42.8)M in Q2 2025 (improvement YoY).
- Diluted earnings per share: Not reported for the quarter.
Business Highlights
- Total revenue rose 22% year‑over‑year for the quarter and 28% year‑to‑date to $730.6M, driven by higher Oncology and Hereditary test volumes.
- Diagnostics remains the primary revenue channel; Data & applications showed strong growth (driven by demand for Insights and the Pathos agreement) and the business is expected to be back‑weighted to the second half.
- Operational scale expanded: test volumes increased to 238k in Q2 from 212k in the prior year period; the Ambry integration increased hereditary testing capacity and contributed full‑period volumes.
- Continued investment in cloud infrastructure, AI and algorithm development, and foundation models (including Pathos work with AstraZeneca) alongside new assay validation efforts.
- Commercial traction broadened with adoption across physicians and pharma: more than 9,000 physicians and over 250 biotech partners, and multi‑year collaborations with AstraZeneca, GSK and Recursion.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.